Breakthrough Pressure Ulcer Prevention

Suspend the Patient.
Eliminate the Ulcer.

DermaFloat is the first patient support system that prevents pressure ulcers by removing surface contact entirely. No compression. No shear. No turning schedules.

2.5M
Americans develop PUs yearly
$26B
Annual US treatment cost
0
Surface pressure with DermaFloat
Zero Contact
Suspension Zone
0 mmHg Interface Pressure
The Problem

Current Solutions Reduce Pressure.
They Don't Eliminate It.

Every existing surface — from basic foam to $50K alternating-pressure mattresses — still compresses tissue. DermaFloat takes a fundamentally different approach.

Pressure Is the Root Cause

Pressure ulcers form when sustained pressure cuts off blood flow to tissue. Every mattress, no matter how advanced, still applies pressure. The only way to truly prevent them is to remove the contact surface.

🕑

Turning Schedules Fail

Q2H repositioning is the standard of care, but compliance rates are as low as 30-50%. Staff shortages, night shifts, and patient resistance make consistent turning nearly impossible at scale.

💰

$26 Billion Problem

Hospital-acquired pressure ulcers cost the US healthcare system $26 billion annually. CMS no longer reimburses for Stage III/IV facility-acquired PUs. Prevention isn't just clinical — it's financial survival.

How It Works

Suspension, Not Compression

DermaFloat uses a medical-grade mesh suspension system that cradles the patient above the frame — distributing weight across the mesh without any point-pressure contact.

1

Mesh Suspension

A breathable, medical-grade mesh is tensioned across an adjustable frame, creating a floating support surface with zero hard contact points.

2

Even Distribution

The patient's weight is distributed across thousands of mesh contact points, keeping interface pressure below capillary closing pressure at every location.

3

Continuous Airflow

The open mesh design allows 360-degree airflow around the patient's body, managing moisture and temperature — two critical factors in skin breakdown.

Interactive Comparison

How DermaFloat Stacks Up

See exactly how DermaFloat compares to the surface technologies your facility is currently using.

Feature Standard Foam Alternating Pressure Low-Air-Loss Manual Turning DermaFloat
Interface Pressure 25-40 mmHg 15-30 mmHg (cycled) 15-25 mmHg Varies (0 when off-loaded) <5 mmHg continuous
Eliminates Shear No No ~ Partial No (causes shear) Yes — mesh conforms
Staff Time Required Q2H turning + skin checks Daily checks Daily checks + maintenance Q2H turning (20 min each) Minimal — monitoring only
Airflow / Moisture Traps heat ~ Some airflow Good airflow N/A 360° open airflow
Noise Level Silent Pump noise (40-55 dB) Blower noise (35-45 dB) N/A (staff disruption) Silent
Power Required None Continuous Continuous None None (passive system)
Estimated Monthly Cost $50-150 $1,500-3,000 $2,000-4,000 $2,400+ (staff time) Competitive — contact us

Standard Foam Mattress

  • 25-40 mmHg pressure
  • No shear elimination
  • Traps heat and moisture
  • Requires Q2H turning
  • ~ $50-150/month

Alternating Pressure

  • ~ 15-30 mmHg (cycled)
  • No shear elimination
  • ~ Some airflow
  • Pump noise 40-55 dB
  • $1,500-3,000/month

Low-Air-Loss

  • ~ 15-25 mmHg pressure
  • ~ Partial shear reduction
  • Good airflow
  • Continuous power needed
  • $2,000-4,000/month
The Evidence

Why This Matters

The clinical and financial case for eliminating pressure ulcers — not just managing them.

60,000

Deaths per year linked to pressure ulcers

Pressure ulcers are a leading contributor to mortality in long-term care patients. They dramatically increase infection risk and complicate recovery from other conditions.

Source: Agency for Healthcare Research and Quality (AHRQ)
$70K

Average cost per Stage IV ulcer

A single Stage IV pressure ulcer can cost $70,000+ to treat — and CMS does not reimburse for facility-acquired cases. Prevention isn't just better care, it's better economics.

Source: Journal of the American Medical Directors Association
30%

Average Q2H turning compliance

Studies show that manual turning schedules are followed only 30-50% of the time. Staff shortages, patient refusal, and overnight gaps make consistent repositioning unreliable.

Source: American Journal of Critical Care
24/7

Continuous prevention with DermaFloat

Unlike turning schedules or alternating pressure cycles, DermaFloat provides continuous, passive pressure elimination. No staff intervention required. No power. No gaps in protection.

Get Started

Request a Demo for Your Facility

See how DermaFloat can reduce pressure ulcer incidence, lower costs, and free up your care team. We'll walk you through the system, discuss your facility's needs, and provide a custom assessment.

  • 📄 Personalized facility assessment
  • 📈 ROI projection based on your bed count
  • 👩‍⚗️ Clinical review with our medical team
  • 🚚 On-site demonstration available

Request a Demo

We'll respond within 24 hours.

Demo Request Received

Thank you. Our team will reach out within 24 hours to schedule your personalized demo and facility assessment.

FAQ

Common Questions

How is DermaFloat different from a low-air-loss mattress?
Low-air-loss mattresses still compress tissue — they just reduce the interface pressure and manage moisture. DermaFloat eliminates the compression surface entirely. The patient is suspended in a mesh, so there are no contact points generating the sustained pressure that causes ulcers. It's a fundamentally different approach: suspension vs. compression reduction.
Is DermaFloat FDA-cleared?
DermaFloat is currently in the regulatory pathway toward FDA clearance. We're working with clinical partners on trials and evidence development. Contact us to learn about pilot programs and early-access opportunities for your facility.
What patient populations is DermaFloat designed for?
DermaFloat is designed for any immobile or limited-mobility patient at risk for pressure ulcers. Primary populations include long-term care residents, ICU patients, post-surgical patients on extended bed rest, spinal cord injury patients, and hospice patients. The system accommodates patients up to the weight capacity of the frame configuration.
How do nurses access the patient for care?
The DermaFloat frame features adjustable side access points and a quick-release mesh system. Nursing staff can perform wound care, bathing, and other bedside procedures without fully removing the patient from the system. The design prioritizes both prevention and practical caregiving workflow.
What does a pilot program look like?
We work with facilities on 60-90 day pilot programs, typically starting with 5-10 units in a high-acuity unit. We provide full training, installation support, and data collection to measure outcomes. Pilots include pre/post incidence tracking, staff satisfaction surveys, and a comprehensive ROI analysis at the end.
Does DermaFloat require electricity or maintenance?
No. DermaFloat is a passive mechanical system — no pumps, no blowers, no electricity. This means zero noise, zero power cost, and no risk of system failure during power outages. The mesh is replaceable and cleanable. Maintenance is limited to periodic mesh inspection and frame checks.

No patient should suffer
because of a surface.

Join the facilities rethinking pressure ulcer prevention. Request your demo today.

Request a Demo →